Background : The worldwide shortage of donor livers has prompted the search for alternative cell therapies for patients suffering from end-stage liver disease, including the transplantation of stem/progenitor cells. As outcome of stem cell therapy in post HCV end stage liver cirrhosis is variable and patients receiving stem cell therapy for non viral end stage liver cirrhosis had better outcome. This study was designed to determine the relation between HCV viral load and the outcome of stem cell therapy in patients with post HCV liver cirrhosis. Methods : We report thirty post HCV liver cirrhosis (LC) patients that underwent bone marrow stem cell (BMSC) transplantation in the portal vein. Subjects were patients with post-HCV LC with abnormal liver functions. G-CSF was administered to suitable patients to increase their haematopoietic stem cells (HSCs) from the bone marrow. HSCs were isolated and separated, CD34+ cells were isolated and injected in the patients. After stem cell therapy, liver function and HCV viral load were monitored for 6 months. Results : There was significant improvement as regards PC and non-significant improvement as regards serum albumin and bilirubin levels . There was improvement in the hepatic functional reserve as assessed by the Child-Pugh score. There was significant improvement as regards performance score (PS). By the end of the study, 63.6% showed improvement and none of the patients showed deterioration of the degree of ascites. The improvement was independent on HCV viral load.Safety of the procedure was evidenced by the low incidence of complications encountered. 7 patients (23.3%) suffered attacks of haematemesis. Conclusions : HSCs therapy may be considered a novel treatment for patients with decompensated LC.